The Connective Issue · Lead Feature
The Steroid Myth in EDS: why the right injection isn’t the enemy
If you live with Ehlers-Danlos syndrome or hypermobility, you have almost certainly been told the same thing I hear in my clinic every week: “Stay away from steroids. They’ll dissolve your tissue.” It is repeated so often in patient forums and even by well-meaning clinicians that it has hardened into a rule. I want to gently push back on that rule — not because the caution is baseless, but because it has been stretched into something the science never actually said.
Where The Fear Comes From
The frightening cases are real — but they are not the whole story
I don’t dismiss the frightening cases. The best-documented harm in EDS comes from high-dose, chronic, systemic corticosteroids — the kind taken as long courses of oral or IV medication. There is a published case of a hypermobility-type EDS patient with no prior wound-healing problems who developed large, non-healing ulcers after high-dose systemic steroid therapy (PubMed). That is a genuine warning, and it is why I am conservative about long systemic courses in fragile-tissue patients.
But “months of systemic steroids” is not the same as “a single, precisely placed injection.” Somewhere along the way those two very different things got collapsed into one blanket prohibition. That is the part I think is overstated.
What The Evidence Shows
The joint literature is dose-dependent
The most important word in the corticosteroid literature is dose-dependent. In a systematic review of intra-articular corticosteroids and cartilage, the harms clustered at high doses, while low doses were associated with increased cell growth and recovery from damage — a protective, not destructive, signal (Orthopaedic Journal of Sports Medicine). A more recent scoping review reached the same conclusion: benefit at low cumulative doses, toxicity only as the dose climbs (PMC).
The kind of steroid matters just as much as the amount. When researchers compared agents directly on inflamed human cartilage cells, a single therapeutic dose of dexamethasone reduced inflammatory gene expression — while triamcinolone, one of the most commonly injected steroids, did not (Scientific Reports). That same study is honest about the flip side: repeated high-dose exposure stresses healthy cells. In other words, the data reward exactly the discipline I practice — the right molecule, a low dose, spaced out, not repeated indefinitely.
And dexamethasone specifically has a chondroprotective track record. In a post-traumatic osteoarthritis model, intra-articular dexamethasone lowered joint inflammation, reduced tissue-degrading enzymes, and protected cartilage that was otherwise breaking down (Journal of Orthopaedic Research). In tendon healing, its benefit is timing-dependent — given in the right window, it improved the quality of the healing tissue (Scientific Reports).
For short-term and acute pain, the efficacy question is essentially settled: meta-analyses of randomized trials show clear early pain relief and functional improvement, which is why guideline bodies recommend intra-articular steroids for exactly that purpose (PubMed, review).
From The Clinic
What I’ve seen in my own practice
I have been treating EDS and hypermobility patients with steroid injections for years — the right agent, at the right dose, at the right time, into the right target. In that time I have not seen the tissue catastrophes the blanket warnings predict. What I have seen, again and again, is meaningful relief, especially for acute, inflammatory flares of pain that were stealing sleep, mobility, and function from people who had been told nothing safe was left to try.
That is the honest calculus I want my patients to understand: for the right patient and the right problem, the benefit outweighs the risk — and the risk, as it is usually described, is overstated. The danger lives in the extremes — high doses, systemic exposure, repeat injections without limit. Avoid those, and a targeted injection becomes one of the most useful tools I have for getting an EDS patient out of an acute pain crisis.
The Takeaway
The goal was never to fear the tool — it was to use it well
Steroids are not off the table in EDS. What matters is route, dose, timing, and technique — and, as always, an accurate diagnosis before the needle ever comes out. A physician who understands connective tissue can use these medications safely. If you have been told to rule steroids out entirely, it may be worth a conversation with a clinician who evaluates the whole picture.
This article is for educational purposes and is not medical advice. Decisions about corticosteroid treatment should be made with your own physician, who can weigh your specific diagnosis, history, and risks. — Dr. J & The Fascia Institute Family